News Sentiment

CMRX sentiment intelligence

Chimerix Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 55 Balanced news tone 45 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 8.54 Week of 19 Jun 2026
Weighted tone 55/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Deals and strategy

71/100 classification confidence.

Company focus 38

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend active

+0.0% over one week, +0.0% over four weeks, trend active, and materially above fair value.

Latest direct headline Neutral

Glioblastoma Multiforme Market to Witness Transformational Growth Opportunities by 2036 – DelveInsight | AstraZeneca, DNAtrix, Chimerix, Northwest Therapeutics, Bayer, Kazia Therapeutics, Aivita Bio

Market Reaction

Balanced read

51/100 confidence

News tone and price action are not far from neutral.

Primary event Deals and strategy 71/100 classification
One-week reaction 0.0% Price digesting
Trend fit Trend active 0.0% over four weeks
Fair value 213.4% Materially above fair value

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 12
Neutral 28
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 38
Industry context 7
Sector context 0

Sources

Coverage mix

Publishers
Market source 5
Stock Titan 4
GlobeNewswire 3
CoinCodex 3
simplywall.st 2
Meyka 2
Insider Monkey 2
PR Newswire 2

Event Lens

What the news is about

Classified themes
Earnings 14
Deals and strategy 14
Market update 12
Regulatory and legal 2
Macro sensitivity 1
Capital return 1
Guidance 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-45 of 45
Nasdaq Direct company coverage

Jazz To Buy Chimerix For $935 Mln To Boost Oncology Portfolio, CMRX Up In Pre-Market

Jazz Pharmaceuticals Plc. announced a deal to acquire Chimerix Inc. for approximately $935 million, or $8.55 per share in cash, representing a 72 percent premium. The acquisition is expected to close in Q2 2025 and aims to boost Jazz's oncology portfolio with Chimerix's lead asse

Tone
Positive 72/100
Event
Deals and strategy
Published
05 Mar 2025 07:53
Source
Nasdaq
Stock Titan Direct company coverage

Jazz Pharma Pays 72% Premium for Chimerix: Is This Rare Disease Drug Worth $935M?

Jazz Pharmaceuticals announced the acquisition of Chimerix for approximately $935 million, representing a 72% premium, to gain control of dordaviprone, a promising drug for rare brain tumors. This acquisition is expected to close in Q2 2025 and positions Jazz for a potential near

Tone
Neutral 50/100
Event
Deals and strategy
Published
05 Mar 2025 07:00
Source
Stock Titan
STAT Direct company coverage

Jazz Pharmaceuticals to acquire Chimerix and its experimental brain cancer drug

Jazz Pharmaceuticals announced its intent to acquire Chimerix for nearly $1 billion, primarily for Chimerix's experimental brain cancer drug, dordaviprone. This drug is aimed at diffuse midline glioma (DMG), a devastating brain tumor, particularly in children and young adults, wh

Tone
Neutral 50/100
Event
Market update
Published
05 Mar 2025 01:40
Source
STAT
Stock Titan Direct company coverage

Chimerix (CMRX) Stock News & Updates

This page provides news and updates on Chimerix (CMRX) stock, a biopharmaceutical company focused on oncology drug development, particularly dordaviprone (ONC201) for H3 K27M-mutant glioma. Key news includes its acquisition by Jazz Pharmaceuticals in April 2025, FDA priority revi

Tone
Positive 80/100
Event
Deals and strategy
Published
13 Jan 2025 01:40
Source
Stock Titan
qz.com Direct company coverage

Chimerix Inc (CMRX) Quarterly 10-Q Report

Chimerix Inc. (CMRX) filed its 10-Q report for the quarter ended September 30, 2024, reporting a net loss of $22.88 million, an improvement from the previous year. Revenue increased to $26,000, primarily due to contract and grant revenue, while R&D expenses rose due to the ACTION

Tone
Negative 39/100
Event
Earnings
Published
07 Nov 2024 00:00
Source
qz.com
Quartz Direct company coverage

Chimerix: Q3 Earnings Snapshot

Chimerix Inc. reported a Q3 loss of $24 million, resulting in a loss of 27 cents per share, which missed Wall Street expectations of a 22-cent loss per share. The biopharmaceutical company recorded a revenue of $11,000 for the period.

Tone
Negative 29/100
Event
Earnings
Published
31 Dec 2023 23:59
Source
Quartz
Stock Titan Direct company coverage

Chimerix to Report Third Quarter 2023 Financial Results and Provide an Operational Update on November 2, 2023

Chimerix announced it will host a live conference call and audio webcast on Thursday, November 2, 2023, at 8:30 a.m. ET to report financial results for the third quarter ended September 30, 2023. The biopharmaceutical company will also provide a business overview during the call.

Tone
Neutral 50/100
Event
Earnings
Published
26 Oct 2023 07:00
Source
Stock Titan